ProCE Banner Activity


Key Studies in Lymphomas and CLL: Independent Conference Coverage of ASH 2022

Conference Coverage
Text Module

Review expert perspectives and insights on the most clinically relevant data for lymphoma and CLL presented at the 2022 American Society of Hematology Annual Meeting.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 17, 2023

Expiration: April 16, 2024

No longer available for credit.



John M. Burke

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Peter Martin

Peter Martin, MD

Chief, Lymphoma Program
Professor of Medicine
Weill Cornell Medicine
Meyer Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie, Amgen, AstraZeneca, Epizyme, GSK, Incyte Corporation, Jazz Pharmaceuticals, Karyopharm Therapeutics Inc, Novartic Pharmaceuticals Corporation, Sanofi, and Seagen.






Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation



Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with malignant or nonmalignant hematologic disorders.

Program Learning Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with malignant or nonmalignant hematologic disorders.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with lymphomas and chronic lymphocytic leukemia (CLL)

  • Evaluate new data on novel agents and therapeutic approaches for patients with lymphomas and CLL

  • Appraise how new trial findings might affect treatment of patients with lymphomas and CLL


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

John M. Burke, MD: consultant/advisor/speaker: Abbvie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Bristol Myers Squibb, Epizyme, Kura, Kymera, MorphoSys, Novartis, Nurix, Roche/Genentech, Seattle Genetics, TG Therapeutics, Verastem, X4 Pharmaceuticals; researcher: MorphoSys; speaker's bureau: BeiGene, Seattle Genetics.

Peter Martin, MD

Chief, Lymphoma Program
Professor of Medicine
Weill Cornell Medicine
Meyer Cancer Center
New York, New York

Peter Martin, MD: consultant/advisor/speaker: ADCT, AstraZeneca, BeiGene, Bristol Myers Squibb, Daiichi Sankyo, Epizyme, Genentech, Gilead, Janssen, Takeda.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 17, 2023, through April 16, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Continuing Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.